The aryl hydrocarbon receptor, or AhR, has long been known as the body’s chemical watchdog. It’s a transcription factor that lies dormant until it encounters specific molecules — ranging from environmental pollutants to natural metabolites — then springs into action to trigger detoxification programs. What makes AhR particularly unusual among its family of bHLH-PAS proteins is that it’s the only member activated by direct ligand binding. Its relatives, such as HIF1α (the hypoxia master regulator) and BMAL1 (the circadian clock driver), rely on other cues. Now, a research team in the United States has revealed a startling second job for AhR: it actively suppresses the ability of nerve cells to regrow after injury, putting it in the crosshairs of regenerative medicine.
When Neurons Face a Crossroads
Following trauma, a damaged neuron must make a critical choice. It can pour resources into managing stress — tidying up misfolded proteins, reshuffling ribosomes, and keeping the cellular house in order — or it can pivot toward mounting a growth response and extending new axons. Peripheral nerves have some capacity to regenerate, but central nervous system fibers, like those in the spinal cord, typically do not. Why this balance tips in one direction has puzzled scientists. The new study, which used both mouse dorsal root ganglion (DRG) neurons and live animals, suggests that AhR is one of the key managers enforcing the stress-coping mode at the expense of regrowth.
The group first checked whether AhR was even present in the right places. They confirmed that Ahr, Hif1a, and their shared binding partner Arnt are expressed in peripheral and central neurons. AhR itself showed classic behavior: an agonist called ITE shuttled the receptor into the nucleus, while an antagonist, CH-223191, trapped it in the cytoplasm. Canonical detoxification targets like Cyp1a1 and Cyp1b1 were switched on or off as expected. Yet the team found no evidence that AhR directly networks with known regeneration-associated transcription factors, hinting at a more indirect but powerful influence.
The group first checked whether AhR was even present in the right places. They confirmed that Ahr, Hif1a, and their shared binding partner Arnt are expressed in peripheral and central neurons. AhR itself showed classic behavior: an agonist called ITE shuttled the receptor into the nucleus, while an antagonist, CH-223191, trapped it in the cytoplasm. Canonical detoxification targets like Cyp1a1 and Cyp1b1 were switched on or off as expected. Yet the team found no evidence that AhR directly networks with known regeneration-associated transcription factors, hinting at a more indirect but powerful influence.
Flipping the Regeneration Switch
When the researchers simply dialed down Ahr levels using knockdown strategies, injured DRG neurons sprouted neurites that were, on average, 21% longer than controls. Pharmacological blockade with AhR antagonists produced the same effect, and the response was dose-dependent — stronger inhibition meant longer outgrowth. Agonists, by contrast, stunted neurite extension. Genetic knockout solidified the story: neurons lacking AhR consistently outperformed their normal counterparts. Not every antagonist worked equally well; BAY-2416964 boosted neurite length, but SR1 did not, revealing a nuance in how different compounds engage the receptor. Interestingly, flooding the system with an agonist in vivo did not worsen regeneration, likely because AhR signaling is tempered by multiple built-in negative feedback loops that prevent runaway activation.
RNA sequencing after injury painted a revealing picture. In wild-type neurons, pathways linked to xenobiotic metabolism and hypoxia surged, with Ahr targets and Hif1a itself climbing. The cells were doubling down on defense. In AhR-deficient neurons, that script flipped. Gone was the heavy investment in proteostasis — the processing of ribosomal RNA, assembly of ribosomes, and clearance of worn-out components. Instead, gene programs supporting de novo protein synthesis, growth signaling, histone modifications, and lipid biosynthesis took center stage. AhR, it seemed, was acting as a metabolic gatekeeper, and removing it allowed neurons to reallocate their internal factories toward building new axons.
RNA sequencing after injury painted a revealing picture. In wild-type neurons, pathways linked to xenobiotic metabolism and hypoxia surged, with Ahr targets and Hif1a itself climbing. The cells were doubling down on defense. In AhR-deficient neurons, that script flipped. Gone was the heavy investment in proteostasis — the processing of ribosomal RNA, assembly of ribosomes, and clearance of worn-out components. Instead, gene programs supporting de novo protein synthesis, growth signaling, histone modifications, and lipid biosynthesis took center stage. AhR, it seemed, was acting as a metabolic gatekeeper, and removing it allowed neurons to reallocate their internal factories toward building new axons.
Real-World Recovery in Mice
Moving from a dish to a living animal, the regenerative potential held up. In the sciatic nerve of mice, axons grew back 50% longer just one day after injury when Ahr was knocked out, and remained 20% longer by day three. Remarkably, this benefit was observed even in aged mice, whose repair machinery is typically sluggish. Crucially, the timing mattered: deleting the gene after injury produced no gains, indicating that AhR’s repressive program is initiated early and must be blocked preemptively or very soon after damage. The effect was not limited to peripheral nerves. In a spinal cord injury model, mice lacking AhR recovered motor function faster and moved more adeptly than controls.
A side finding served as a cautionary tale. Indole-3-propionate, a gut microbe-derived metabolite previously linked to axon regeneration through immune cell chemotaxis, did not spur neurite outgrowth in this system. This underscores that not all AhR-interacting metabolites push the same physiological buttons; context and cell type are everything.
A side finding served as a cautionary tale. Indole-3-propionate, a gut microbe-derived metabolite previously linked to axon regeneration through immune cell chemotaxis, did not spur neurite outgrowth in this system. This underscores that not all AhR-interacting metabolites push the same physiological buttons; context and cell type are everything.
The HIF1α Link and a Translational Takeaway
How does AhR exert its brake? The data point to the mTOR pathway, a central controller of protein synthesis. AhR appears to dampen mTOR activity and restrain ribosomal processing, capping the neuron’s ability to manufacture new proteins. Remove AhR, and the translational machinery whirs back to life. Intriguingly, this liberation requires an intact HIF1α–ARNT axis. When the researchers pharmacologically inhibited HIF1α translation, the regenerative boost from Ahr knockout vanished, revealing a collaborative interplay between these two PAS-family members rather than a simple rivalry.
The findings turn AhR from a mere toxicant sensor into a potential therapeutic target for nerve repair. Small-molecule AhR antagonists, possibly administered shortly after injury, might coax central and peripheral neurons out of their defensive crouch and into a growth-permissive state. For a field that has struggled to overcome the spinal cord’s stubborn refusal to heal, discovering that a well-studied receptor can act as a molecular handbrake offers a fresh and druggable way forward.
The findings turn AhR from a mere toxicant sensor into a potential therapeutic target for nerve repair. Small-molecule AhR antagonists, possibly administered shortly after injury, might coax central and peripheral neurons out of their defensive crouch and into a growth-permissive state. For a field that has struggled to overcome the spinal cord’s stubborn refusal to heal, discovering that a well-studied receptor can act as a molecular handbrake offers a fresh and druggable way forward.
Publication date: 2026.04.10
Source:
Halawani D. et al. AhR inhibition promotes axon regeneration via a stress-growth switch. Nature. 2026 May;653(8116):1119-1129. doi: 10.1038/s41586-026-10295-z. Epub 2026 Apr 1. PMID: 41922778; PMCID: PMC13216071.
https://www.nature.com/articles/s41586-026-10295-z#Sec7
Source:
Halawani D. et al. AhR inhibition promotes axon regeneration via a stress-growth switch. Nature. 2026 May;653(8116):1119-1129. doi: 10.1038/s41586-026-10295-z. Epub 2026 Apr 1. PMID: 41922778; PMCID: PMC13216071.
https://www.nature.com/articles/s41586-026-10295-z#Sec7